NLRP3 and hepatocellular carcinoma: It is exciting to find that the AL365361.1/hsa-miR-17-5p/NLRP3 axis may inhibit HCC progression and may be related to the ICIs sensitivity of HCC patients, which is the main reason for the difference in immune response and OS between the two risk groups.